Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.

Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing

Shares of Mirati Therapeutics Inc. MRTX, -2.40% were down 4.7% premarket on Friday after the company said the European Medicines Agency had issued a negative opinion on a marketing application for Krazati, a treatment for non-small cell lung cancer. “Mirati disagrees with the opinion and intends to request a formal re-examination,” the company said in a release Friday.

Mirati Therapeutics shares fall after lung cancer drug gets negative opinion from European regulators

SAN DIEGO and ZUG, Switzerland , July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for KRAZATI® (adagrasib) for treatment of patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC). Mirati disagrees with the opinion and intends to request a formal re-examination.

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation

Mirati Therapeutics said on Friday the European regulator's panel for medical products has declined to recommend an authorization for the company's drug to treat of a type of lung cancer.

EU regulator declines to back Mirati's lung cancer drug

SAN DIEGO , June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ®  (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher. "I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek , chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer.

Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

Adagrasib is the first and only KRASG12C inhibitor to prospectively demonstrate intracranial (IC) activity in KRASG12C-mutated NSCLC with untreated CNS metastases  Data demonstrate compelling clinical activity; highlights promising and durable intracranial clinical activity  Data follows recent inclusion of adagrasib as first and only KRAS G12C inhibitor listed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for CNS Cancers  SAN DIEGO , June 20, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ®  (NASDAQ: MRTX), a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published clinical results from the KRYSTAL-1 study of adagrasib, a potent and selective KRASG12C inhibitor, demonstrating durable IC activity in patients living with KRASG12C-mutated NSCLC with untreated CNS metastases. This result is clinically meaningful as CNS metastases are present in 27%-42% of patients living with KRASG12C-mutated NSCLC at diagnosis and are linked to worse prognosis and higher rates of disease progression in the CNS.

Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases

SAN DIEGO , June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m.

Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023

Data follows recent inclusion of Adagrasib in NCCN Guidelines for PDAC and CNS Cancers Additional Company Presentations Highlight Real-World Observations in Patients Living with Metastatic NSCLC and KRASG12C Mutated NSCLC SAN DIEGO , May 30, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ®  (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types. The company will present encore data indicating adagrasib, a potent and selective KRASG12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with previously treated pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid tumors harboring a KRASG12C mutation.

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting

Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.

Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%

SAN DIEGO , May 24, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.®  (NASDAQ: MRTX), a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy.

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday.

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Ryan Asay – Vice President-Corporate Affairs David Meek – Chief Executive Officer Ben Hickey – Chief Commercial Officer Alan Sandler – Chief Medical Officer Jamie Christensen – Chief Scientific Officer Laurie Stelzer – Chief Financial Officer Conference Call Participants Michael Schmidt – Guggenheim Tyler Van Buren – TD Cowen Gena Wang – Barclays Jonathan Miller – Evercore ISI Mike Ulz – Morgan Stanley Ben Burnett – Stifel Maury Raycroft – Jefferies Silvan Tuerkcan – JMP Securities Eric Joseph – JPMorgan Yigal Nochomovitz – Citi Andy Fleszar – B. Riley Securities Jay Olson – Oppenheimer Ami Fadia – Needham Operator Good afternoon, and welcome to the Mirati Therapeutics First Quarter 2023 Earnings Call.

Mirati Therapeutics, Inc. (MRTX) Q1 2023 Earnings Call Transcript

Mirati (MRTX) came out with a quarterly loss of $3.18 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.40 per share a year ago.

Mirati (MRTX) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO , May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor.

Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

SAN DIEGO and NASHVILLE, Tenn. , May 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.®  (NASDAQ: MRTX), a commercial stage biotechnology company, and Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.

Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies

SAN DIEGO , April 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T. / 1:00 p.m.

Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference

Data demonstrates compelling clinical activity, highlights adagrasib potential as monotherapy in solid tumors Clinical data also presented at the ASCO Plenary Series: April 2023 Session Data follows recent inclusion of KRAZATI® (adagrasib) in NCCN Guidelines for CNS Cancers SAN DIEGO , April 26, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ®  (NASDAQ: MRTX), a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRASG12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid tumors harboring a KRASG12C mutation. Rapid Communications are reserved for publications deemed to represent timely and late breaking research that may have an immediate impact on patient care.

Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors

SAN DIEGO , April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m.

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

Preclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options SAN DIEGO , April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approved product. Krazati is used to treat adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Mirati's Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market

Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?

Amylyx Pharmaceuticals

Apellis Pharma

Ascendis Pharma

Axsome Therapeutics

Cogint

CTI BioPharma

IVERIC bio Inc

Reata Pharmaceuticals

Seagen

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

These Are the Top 10 Holdings of David Kim

SAN DIEGO , March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. / 9:00 a.m.

Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference

Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.

Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Ryan Asay - VP of Corporate Affairs David Meek - CEO Charles Baum - President, Founder and Head of R&D Laurie Stelzer - CFO James Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Alan Sandler - Chief Medical Officer Conference Call Participants Tyler Van Buren - Cowen and Company Salveen Richter - Goldman Sachs Harshita Polishetty - Barclays Jonathan Miller - Evercore ISI Michael Schmidt - Guggenheim Neil Carnahan - Stifel Noah Burhance - JPMorgan Jason Gerberry - Bank of America Michael Ulz - Morgan Stanley Yigal Nochomovitz - Citigroup Maury Raycroft - Jefferies Evan Seigerman - BMO Ami Fadia - Needham Andrew Fleszar - B. Riley Securities Jay Olson - Oppenheimer Operator Good afternoon and welcome to the Mirati Therapeutics Fourth Quarter 2022 Earnings Call.

News for Mirati Therapeutics Stock (MRTX)